C4 Therapeutics (CCCC) AI Stock Analysis

• Market Cap: $225.81M
• Dividend Yield: N/A
• Average Volume (3M): 1.67M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.29
• Revenue Growth: -10.57%
• EPS Growth: 1.98%
• Country: US
• Employees: 110
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 96,914,420
• 10 Day Avg. Volume: 1,200,811
• 30 Day Avg. Volume: 1,668,550
• PEG Ratio: 0.06
• Price to Book (P/B): 1.16
• Price to Sales (P/S): 7.02
• P/FCF Ratio: -3.82
• Enterprise Value/Market Cap: 0.14
• Enterprise Value/Revenue: 1.02
• Enterprise Value/Gross Profit: 1.08
• Enterprise Value/Ebitda: -0.25
• 1Y Price Target: $6.00
• Price Target Upside: 157.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -1.31
• Revenue Forecast (FY): $21.94M

• Rating: 44 Neutral
• Price Target: $2.00 ▼(-14.16% Downside)

The score is driven primarily by weak financial performance (large ongoing losses and substantial cash burn), which outweighs the improved liquidity outlook from the recent financing. Technicals are mixed but generally soft (below key moving averages with negative MACD), and valuation is constrained by negative earnings and no dividend.

Positive Factors

Proprietary TORPEDO platform

The TORPEDO platform represents a structural R&D advantage: targeted protein degradation is a differentiated therapeutic approach versus inhibition. A successful platform can produce multiple clinic-ready assets, create licensing or partnership optionality, and sustain long-term pipeline value beyond single trial outcomes.

Gross profit generation on revenue

Positive gross profit indicates the company’s underlying products or services can cover direct costs, implying scalable unit economics as programs mature. This supports eventual margin expansion if revenue grows and R&D spend stabilizes, making future profitability more attainable than for firms without gross-profit generation.

Extended cash runway from offering

The announced $117M financing materially extends runway to end-2028, reducing near-term funding pressure and allowing the company to advance clinical programs and pursue value-creating milestones. Structurally, this lowers immediate dilution risk and gives management time to de-risk assets or secure partnerships.

Negative Factors

Heavy cash burn

Sustained negative operating and free cash flow show the business consumes significant cash to fund development, necessitating recurrent capital raises. Over the next several months this amplifies dependency on financing events, risks dilution, and constrains strategic flexibility if clinical timelines slip or costs rise.

Large operating losses

Deep and persistent operating losses reflect heavy R&D investment without offsetting revenue, pressuring equity and returns. Until clinical candidates advance toward revenue-generating or partnerable milestones, these losses will structurally weaken profitability metrics and increase the likelihood of future dilutive financing.

Declining revenue and shrinking equity

Falling revenue and materially reduced equity indicate weaker commercial traction and cumulative losses eroding the balance sheet. This trend raises leverage and financing vulnerability, reducing long-term financial flexibility and increasing the probability of unfavorable capital raises or constrained investment in core programs.

C4 Therapeutics Business Overview & Revenue Model

Company Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

C4 Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies that seek to leverage its proprietary protein degradation technology. The company may receive upfront payments, milestone payments tied to the achievement of specific development goals, and royalties on sales of products developed through these collaborations. Additionally, C4 Therapeutics may engage in grant funding or government contracts to support research and development efforts. The success of its revenue model is heavily reliant on the advancement of its drug candidates through clinical trials and their eventual commercialization in partnership with established pharmaceutical companies.

C4 Therapeutics Financial Statement Overview

Summary

C4 Therapeutics faces significant financial challenges, with persistent losses impacting profitability and cash flows. While the balance sheet remains relatively stable, the company needs to address its operational inefficiencies to improve financial health. Strategic adjustments may be necessary to enhance revenue generation and cost management to achieve sustainable growth.

Income Statement

The income statement reveals a company struggling with profitability. The TTM (Trailing-Twelve-Months) shows negative EBIT and net income, indicating operational challenges. Although there's a modest revenue growth of 11.8% from the previous year, margins remain negative, suggesting ongoing difficulties in cost management or revenue generation.

Balance Sheet

The balance sheet shows a reasonable equity ratio of 61.07%, indicating a solid capital structure with more assets funded by equity. However, the debt-to-equity ratio of 0.33 reflects manageable leverage but could pose risks if financial performance does not improve. Return on equity remains negative due to ongoing losses.

Cash Flow

Cash flow analysis indicates issues with cash generation, as both operating and free cash flows are negative in the TTM (Trailing-Twelve-Months). The operating cash flow to net income ratio is negative, pointing to inefficiencies in converting sales into cash, while free cash flow is deteriorating, signaling cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	30.11M	35.58M	20.76M	31.10M	45.78M	33.20M
Gross Profit	28.34M	35.58M	13.02M	31.10M	45.78M	-45.24M
EBITDA	-120.98M	-103.37M	-122.10M	-124.28M	-80.25M	-58.83M
Net Income	-119.08M	-105.32M	-132.49M	-128.18M	-83.89M	-66.33M
Balance Sheet
Total Assets	265.49M	349.60M	376.45M	430.84M	506.76M	400.14M
Cash, Cash Equivalents and Short-Term Investments	191.88M	244.90M	253.68M	276.15M	309.28M	371.69M
Total Debt	61.46M	65.76M	70.98M	87.15M	42.88M	22.92M
Total Liabilities	111.08M	133.62M	130.34M	141.61M	117.16M	119.35M
Stockholders Equity	154.41M	215.99M	246.11M	289.23M	389.61M	280.79M
Cash Flow
Free Cash Flow	-95.07M	-65.34M	-108.55M	-111.44M	-88.24M	-67.90M
Operating Cash Flow	-94.48M	-65.16M	-106.84M	-105.94M	-86.97M	-67.25M
Investing Cash Flow	85.80M	-51.27M	158.35M	58.42M	-189.34M	-190.50M
Financing Cash Flow	7.84M	45.34M	45.49M	1.15M	171.40M	348.93M

C4 Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Neutral. The current price of 2.33 is above the 20-day moving average (MA) of 2.09, above the 50-day MA of 2.33, and above the 200-day MA of 2.08, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 50.47 is Neutral, neither overbought nor oversold. The STOCH value of 72.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CCCC.

C4 Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLS	56 Neutral	$585.44M	-13.38	-84.33%	―	―	59.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MCRB	50 Neutral	$145.47M	25.00	15.95%	―	448.44%	―
CCCC	44 Neutral	$225.81M	-1.33	-59.98%	―	-10.57%	1.98%
ELDN	44 Neutral	$152.42M	-1.72	-95.49%	―	―	72.35%
TVGN	41 Neutral	$63.16M	-1.84	―	―	―	-234.46%

C4 Therapeutics Corporate Events

C4 Therapeutics Unveils Multi-Year Cemsidomide Clinical Strategy

On January 14, 2026, C4 Therapeutics outlined a multi-year strategy centered on advancing its lead IKZF1/3 degrader cemsidomide toward potential best-in-class status in multiple myeloma, alongside a refocused discovery effort on novel targets in validated inflammatory and neuro-inflammatory pathways. The company plans to start the Phase 2 MOMENTUM trial of cemsidomide plus dexamethasone in the first quarter of 2026 using a 100 µg dose, initiate a Phase 1b study with elranatamab in the second quarter of 2026, and work toward pivotal data readouts and a potential U.S. new drug application in fourth-line or later multiple myeloma by year-end 2028, supported by Phase 1 data from 2025 showing overall response rates of 40% and 53% at the two highest dose levels. C4T also detailed a goal to begin a Phase 3 trial of cemsidomide in combination with a BCMA bispecific antibody by early 2028, use data from its CFT8919 program in China to guide ex-China development in 2026, and file up to three investigational new drug applications from its internal discovery pipeline by 2028. The company reported that its cash runway extends to the end of 2028, providing funding through several clinical and partnership milestones, including advancement of collaborations with Merck KGaA, Roche and Biogen, positioning C4T to strengthen its presence in targeted protein degradation and potentially enhance value for patients and investors if the planned trials and discovery initiatives succeed.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

C4 Therapeutics Announces Stock and Warrants Offering

On October 16, 2025, C4 Therapeutics announced an underwritten offering of common stock and warrants, expected to close on October 17, 2025. The company anticipates net proceeds of approximately $117 million, extending its cash runway to the end of 2028, with potential total proceeds reaching $341.7 million if all warrants are exercised.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

C4 Therapeutics Presents Phase 1 Trial Data

On October 16, 2025, C4 Therapeutics announced the presentation of data from its Phase 1 clinical trial of cemsidomide combined with dexamethasone for relapsed/refractory multiple myeloma, highlighting its potential efficacy and safety profile. Additionally, the company terminated a sales agreement prospectus with TD Securities, impacting its stock sale strategy, while maintaining the agreement’s validity for future use, having previously raised approximately $9.6 million through stock sales.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.